Lupin has completed the acquisition of the diabetes brands Ondero and Ondero Met from Boehringer Ingelheim International.
The acquisition encompasses the trademark rights associated with these brands. Lupin has been actively marketing Ondero and Ondero Met in the Indian market since 2015 through a co-marketing agreement with Boehringer Ingelheim India.
In India, where a substantial portion of the population is affected by Type-2 Diabetes, with approximately 77 million individuals above 18 years of age, and nearly 25 million in a pre-diabetic state, the significance of diabetes management is evident.
Ondero (Linagliptin) and Ondero Met (a combination of Linagliptin and Metformin) have established themselves as the gold standard in diabetes management.
This strategic acquisition underscores Lupin’s dedication to enhancing its offerings for patients grappling with the challenges of diabetes. By expanding its portfolio with these brands, Lupin aims to provide even more effective treatment options to individuals dealing with this prevalent and complex condition.
Lupin managing director Nilesh Gupta said: “Lupin is at the forefront of providing quality pharmaceutical products to patients. With the acquisition of Ondero and Ondero Met, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment.”
Lupin India Region Formulations president Rajeev Sibal said: “The disease burden of diabetes is constantly increasing fuelled by the prevalence of obesity and unhealthy lifestyles. This important acquisition reflects our steadfast dedication in empowering healthcare professionals to combat the growing menace of diabetes in India and significantly improve the lives of those facing this challenging disease.”
